PHARMA COMPANIES TO DEVELOP FLU VACCINES WITH ADJUVANT

FEBRUARY 01, 2007

The US Department of Health and Human Services has awarded $132.5 million to 3 pharmaceutical companies for the advanced development of H5N1 influenza vaccines using an adjuvant—an immune system booster. The government has given the companies the task of developing bird-flu vaccines using adjuvants, which increase the body's immune response. Less of this type of vaccine should be required for protection.

The agency awarded $54.8 million to Novartis, $63.3 million to GlaxoSmith- Kline, and $14.4 million to Iomai of Maryland. Under the contracts, each company will increase its capacity to produce—within 6 months after the start of an influenza pandemic—either 150 million doses of an adjuvant-based pandemic influenza vaccine or sufficient adjuvant for 150 million doses of a pandemic influenza vaccine.




SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.